Cantex Pharma’s Azeliragon Therapy: A Potential Cancer Breakthrough
In this interview, Dr. Stephen Marcus, CEO of Cantex Pharmaceuticals, discusses the innovative cancer therapy, Azeliragon. He explores its...
Moe Alsumidaie
Industry and FDA Insights on Clinical Trial Regulatory Change
At the Duke-Margolis Institute for Health Policy conference, industry and government leaders delved into the future of clinical trials...
FDA On Clinical Trial Innovation and Regulatory Evolution
The Enhancing Adoption of Innovative Clinical Trial Approaches: FDA Convening conference hosted by Duke Margolis Institute for Health Policy,...
Merck’s Approach to Protocol Development: Building with Purpose:
At the 2024 SCOPE Summit, Laura Galuchie, Senior Director and TransCelerate Program Lead at Merck provided a fresh perspective...
Unlocking New Digital Health Technology in Clinical Trials
In the rapidly evolving landscape of digital health technology in clinical trials (DHT), Jeremy Wyatt, CEO of ActiGraph, envisions...
Abbvie Leads The Way With DHTs in Clinical Trials
At the 2024 SCOPE Summit, AbbVie’s Digital Science Head, Michelle Crouthamel, presented compelling case studies on Aleve PM and...
AI-Driven Pathology: A New Era of Precision Clinical Trials
PathAI emerges as an enterprise transforming clinical trials with groundbreaking precision in the dynamic field of AI-driven pathology. Ben...
Clinical Trial Complexity: A Unique Challenge Tackled
As clinical trial complexity continues to rise, effective technology is paramount. In this interview, we discussed clinical trial technology...
How Pfizer Uses AI to Transform Clinical Trial Data Oversight
At the 2024 SCOPE Summit, Demetris Zambas, VP and Global Head of Data Monitoring and Management at Pfizer explored...
Digital Twin Drug Development: The Future of Clinical Trials
In the fast-changing world of pharmaceutical drug development, new digital twin technologies are beginning to make a significant impact....